Etanercept in psoriasis treatment

Aldona Pietrzak; Grazyna Chodorowska; Janusz Urban; Jacek Roliński; Bogusław Pietrzak

Etanercept in psoriasis treatment

Ann Univ Mariae Curie Sklodowska Med. 2003;58(1):222-6.

Authors

Aldona Pietrzak¹, Grazyna Chodorowska, Janusz Urban, Jacek Roliński, Bogusław Pietrzak

Affiliation

¹ Chair and Department of Dermatology, Medical University of Lublin, Lublin, Poland.

PMID: 15314989

Abstract

More recently, lots of new drugs regulating the several steps of immune reaction have been introduced for psoriasis treatment. These include TNF-alpha inhibitors. One of such inhibitors is Etanercept--a monoclonal antibody connected with human IgG1 binding the soluble form of TNF-alpha receptor. We present the literature data concerning the attempts of Etanercept treatment and local and general complications of its use.

Publication types

Review

MeSH terms

Drug Therapy, Combination
Etanercept
Humans
Immunoglobulin G / adverse effects
Immunoglobulin G / therapeutic use*
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Psoriasis / drug therapy*
Psoriasis / immunology
Receptors, Tumor Necrosis Factor / therapeutic use*
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Tumor Necrosis Factor-alpha / immunology

Substances

Immunoglobulin G
Immunosuppressive Agents
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
Etanercept